In vivo veritas, the next frontier for functionally selective GPCR ligands

Area of Science:

• Pharmacology
• Molecular Biology
• Drug Development

Background:

• G-protein coupled receptors (GPCRs) activate multiple signaling pathways simultaneously.
• Biased ligands selectively target specific downstream responses of a receptor.
• Existing tools for identifying biased ligands primarily use in vitro recombinant cell systems.

Purpose of the Study:

• To present a general strategy for validating biased ligand activity in vivo.
• To support the development of biased ligands as a viable drug development strategy.
• To differentiate between G-protein and beta-arrestin mediated signaling mechanisms in vivo.

Main Methods:

• Development of a general strategy for in vivo validation of biased ligands.
• Focus on discriminating between G-protein and beta-arrestin signaling pathways.
• Analysis of differences between in vitro and in vivo experimental systems.

Main Results:

• A validated strategy for assessing biased ligand activity in animal models.
• Insights into distinguishing G-protein versus beta-arrestin signaling in vivo.
• Identification of challenges and opportunities for in vivo biased ligand development.

Conclusions:

• In vivo validation is crucial for the advancement of biased ligand therapeutics.
• The presented strategy facilitates the translation of biased ligands to pre-clinical models.
• Further tool development is needed to streamline in vivo biased ligand assessment.